Benutzerspezifische Werkzeuge
Sie sind hier: Startseite Collaborative Research Center 655 Publications B13-Hofbauer / Platzbecker

B13: SFB-relevant publications

  • Bauer W, Rauner M, Haase M, Kujawski S, Arabanian LS, Habermann I, Hofbauer LC, Ehninger G, and Kiani A (2011): Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. Haematologica 96, 1580-1588.
  • Eskan MA, Jotwani R, Abe T, Chmelar J, Lim JH, Liang S, Ciero PA, Krauss JL, Li F, Rauner M, Hofbauer LC, Choi EY, Chung KJ, Hashim A, Curtis MA, Chavakis T, and Hajishengallis G (2012): The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nature Immunol 13, 463-473.
  • Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, and Riggs BL (2000): The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141, 4768-4776.
  • Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CJ, Asuncion FJ, Ominsky MS, and Hofbauer LC (2012): Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res . doi: 10.1002/jbmr.1803. [Epub ahead of print].
  • Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, Klut IM, Knoth H, Röllig C, Schetelig J, Mohr B, Graehlert X, Ehninger G, Bornhäuser M, and Thiede C (2012a): Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26, 381-389.
  • Platzbecker U, Hofbauer LC, Ehninger G, and Hölig K (2012b): The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 36, 525-536.
  • Rauner M, Stein N, Winzer M, Goettsch C, Zwerina J, Schett G, Distler JH, Albers J, Schulze J, Schinke T, Bornhäuser M, Platzbecker U, and Hofbauer LC (2012): WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 27, 575-585.
  • Salbach J, Kliemt S, Rauner M, Rachner TD, Goettsch C, Kalkhof S, von Bergen M, Möller S, Schnabelrauch M, Hintze V, Scharnweber D, and Hofbauer LC (2012): The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. Biomaterials 33, 8418-8429.
  • Shroff RC, Beringer O, Rao K, Hofbauer LC*, and Schulz A* (2012): Denosumab for post-transplant hypercalcemia in osteopetrosis. New Engl J Med 367, 1766-1767. *Shared senior authorship.
  • Thiele S, Rauner M, Goettsch C, Rachner TD, Benad P, Fuessel S, Erdmann K, Hamann C, Baretton GB, Wirth MP, Jakob F, and Hofbauer LC (2011): Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem 112, 1593-1600.
  • Wermke M, Schmidt A, Middeke JM, Sockel K, von Bonin M, Schönefeldt C, Mair A, Plodeck V, Laniado M, Weiss G, Schetelig J, Ehninger G, Theurl I, Bornhäuser M, and Platzbecker U (2012): Magnetic resonance imaging-based liver iron content predicts for non-relapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res 18:6460-6468.
  • Wobus M, Benath G, Ferrer RA, Wehner R, Schmitz M, Hofbauer LC, Rauner M, Ehninger G, Bornhäuser M, and Platzbecker U (2012): Impact of lenalidomide on functional properties of human mesenchymal stromal cells. Exp Hematol 40, 867-876.


« Juni 2019 »

Funding program: